Agomab Therapeutics (AGMB) CBO details stock option grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Agomab Therapeutics NV Chief Business Officer Paul Henryk van der Horst has reported his derivative equity holdings in a Form 3. The filing lists several stock options to buy Agomab common shares at exercise prices of $0.0005 and $14.2600 per share.
The options cover different blocks of underlying common shares, with expiration dates ranging from 2031-03-05 through 2036-01-15. Footnotes state that some shares underlying these options are fully vested and exercisable, while others vest over time in monthly installments, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
van der Horst Paul Henryk
Role
Chief Business Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 114,070 shares (Direct)
Footnotes (1)
- The shares underlying this option are fully vested and exercisable. The common shares may be represented by American Depositary Shares, each of which currently represents one common share. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
FAQ
What does the Agomab Therapeutics (AGMB) Form 3 filing show for Paul Henryk van der Horst?
The Form 3 shows that Agomab’s Chief Business Officer holds several stock options over common shares. These options have different expiration dates and exercise prices, giving him potential future equity exposure if he chooses to exercise them.
What types of securities does Paul Henryk van der Horst report in Agomab Therapeutics (AGMB) Form 3?
He reports multiple derivative positions classified as stock options, each described as a "Stock Option (Right to Buy)" over Agomab common shares. These options provide the right, but not the obligation, to purchase common shares at preset exercise prices.
What are the exercise prices of the options reported in the Agomab Therapeutics (AGMB) Form 3?
The options have exercise prices of $0.0005 and $14.2600 per common share, reported in U.S. dollars. A footnote explains these prices reflect conversion from euros using an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.
When do the stock options reported by Agomab Therapeutics (AGMB) CBO expire?
The reported stock options have expiration dates between 2031-03-05 and 2036-01-15. Each grant specifies a distinct expiration date, defining how long the Chief Business Officer has the right to exercise those options for Agomab common shares.
Are the Agomab Therapeutics (AGMB) options held by Paul Henryk van der Horst vested?
A footnote states that the shares underlying one option grant are fully vested and exercisable, while others vest over time. Additional footnotes describe vesting schedules with portions vesting initially and remaining shares vesting in equal monthly installments, contingent on continued service.